|
Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Endocyte |
Research Funding - Bayer (Inst); Endocyte (Inst); Progenics (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bayer; Endocyte |
|
|
|
Stock and Other Ownership Interests - Caris Life Sciences |
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Dendreon; Endocyte; Janssen Oncology; Mannkind; Pfizer; UpToDate |
Consulting or Advisory Role - Amgen; AVEO; Bayer; BIND Biosciences; Cerulean Pharma; Churchill Pharmaceuticals; Genentech/Roche; HERON; Janssen Biotech; Labceutics; Pfizer |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi |
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Endocyte |
Patents, Royalties, Other Intellectual Property - Endocyte |
Travel, Accommodations, Expenses - Endocyte |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Honoraria - Astellas Pharma; Bayer; Bellicum Pharmaceuticals; Exelixis; Ferring; Genentech; Johnson & Johnson; Medivation; Merck Serono; Millennium; Pfizer; Progenics; Sanofi |
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Sanofi |
Research Funding - Astellas Medivation; Dendreon; Endocyte; Genentech; gtx; Johnson & Johnson; Merck; Millennium; Novartis; Oncogenex; progenics; Progenics; Sanofi |
Expert Testimony - Celgene; sanofi |
Travel, Accommodations, Expenses - Bayer; Bellicum Pharmaceuticals; Celgene; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Oncogenex; Pfizer; Progenics; Sanofi |
|
|
|
Leadership - Symphony Evolution |
Consulting or Advisory Role - Akebia Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Bayer Schering Pharma (Inst); Bicycle Therapeutics (Inst); Blend Therapeutics (Inst); Boehringer Ingelheim (Inst); Celator (Inst); Elekta (Inst); Endocyte (Inst); Genmab (Inst); Heron (Inst); Ignyta (Inst); Janssen (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Upsher-Smith (Inst); Zymeworks (Inst) |
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); TaiRx, Inc. (Inst) |
|
|
Stock and Other Ownership Interests - Caremission; WCCT Global |
Consulting or Advisory Role - Castle Biosciences; Deciphera; RedHill Biopharma |
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Calithera Biosciences (Inst); Celldex (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MedImmune (Inst); Merck Serono (Inst); Millennium (Inst); OncoMed (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Sirtex Medical (Inst); Tokai Pharmaceuticals (Inst); TRACON Pharma (Inst) |
|
|
Consulting or Advisory Role - Celgene; Endocyte |